Citi raised the firm’s price target on DexCom (DXCM) to $77 from $75 and keeps a Buy rating on the shares. Citi also opened an “upside 90-day catalyst watch” on DexCom. The firm sees the stock moving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback